In the current viral pandemic, it is worth recalling that brain cancers will arise during and after the epidemic. The core business case for Kazia remains strong as it is developing the only brain penetrating PI3K inhibitor agent in trials to treat glioblastoma. In the current Phase II, the 21-patient expansion cohort was fully recruited in February. No hospitalisation is needed to continue with this study; it is oral dosing. The potentially pivotal Phase III using the AGILE trial network is
31 Mar 2020
Kazia Therapeutics - Paxalisib trial still on track for H220 start
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Kazia Therapeutics - Paxalisib trial still on track for H220 start
- Published:
31 Mar 2020 -
Author:
Dr John Savin -
Pages:
3
In the current viral pandemic, it is worth recalling that brain cancers will arise during and after the epidemic. The core business case for Kazia remains strong as it is developing the only brain penetrating PI3K inhibitor agent in trials to treat glioblastoma. In the current Phase II, the 21-patient expansion cohort was fully recruited in February. No hospitalisation is needed to continue with this study; it is oral dosing. The potentially pivotal Phase III using the AGILE trial network is